This Phase 2 study is looking at a drug called sonefpeglutide (HM15912) for adults with Short Bowel Syndrome (SBS), a condition where your body can't absorb enough nutrients because part of your small intestine is missing or not working well. The main goal is to see how safe sonefpeglutide is by tracking any side effects over 24 weeks. You might be able to join if you are 18 or older and have SBS that causes intestinal failure. Some participants will receive sonefpeglutide, while others will receive a placebo (an inactive substance). The study is currently unclear about its recruitment status, but it plans to enroll 18 people.

Study design

This is a randomized, double-blind, placebo-controlled Phase 2 study, meaning participants are randomly assigned to receive either sonefpeglutide or a placebo, and neither you nor your doctor will know which you are receiving. The study plans to enroll 18 participants.

What's involved

The study involves a screening period, a run-in period, a 6-month core treatment period, a 7-month extension treatment period, and a 1-month safety follow-up period.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for safety for one month after the treatment period ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.